C
TVTX icon

Covestor’s Travere Therapeutics TVTX Stock Holding History

Covestor’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
6
– – ﹤0.01% 2782
2025
Q4 		$0 Hold
6
– – ﹤0.01% 2749
2025
Q3 		$0 Hold
6
– – ﹤0.01% 2789
2025
Q2 		$0 Sell
6
-1
-14% -$17 ﹤0.01% 2771
2025
Q1 		$0 Hold
7
– – ﹤0.01% 2742
2024
Q4 		$0 Sell
7
-4
-36% -$71 ﹤0.01% 2753
2024
Q3 		$0 Hold
11
– – ﹤0.01% 2783
2024
Q2 		$0 Sell
11
-1
-8% -$7 ﹤0.01% 2773
2024
Q1 		$0 Hold
12
– – ﹤0.01% 2758
2023
Q4 		$0 Buy
12
+5
+71% +$36 ﹤0.01% 2733
2023
Q3 		$0 Sell
7
-1
-13% -$14 ﹤0.01% 2730
2023
Q2 		$0 Sell
8
-1
-11% -$18 ﹤0.01% 2669
2023
Q1 		$0 Hold
9
– – ﹤0.01% 2603
2022
Q4 		$0 Hold
9
– – ﹤0.01% 2623
2022
Q3 		$0 Sell
9
-2
-18% -$52 ﹤0.01% 2624
2022
Q2 		$0 Sell
11
-3
-21% -$75 ﹤0.01% 2376
2022
Q1 		$0 Sell
14
-3
-18% -$80 ﹤0.01% 2450
2021
Q4 		$1K Buy
+17
New +$479 ﹤0.01% 1963

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Covestor's TVTX Position: Q1 2026 in Review

Covestor held its Travere Therapeutics (TVTX) position steady in Q1 2026 at 6 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2782.

Covestor first reported a position in TVTX in Q4 2021 and has held it in 18 quarters since. The position peaked at $1K in Q4 2021. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Covestor held 6 shares of Travere Therapeutics worth $0 as of Q1 2026.
  • Covestor left its Travere Therapeutics share count unchanged in Q1 2026.
  • Travere Therapeutics made up ﹤0.01% of Covestor's portfolio in Q1 2026, its #2782 holding.
  • Covestor first reported a position in Travere Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Covestor's Travere Therapeutics position peaked at $1K in Q4 2021.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Covestor's 13F filing for Q1 2026, filed 5 May 2026.